Bactiguard wins CVC tender in Sweden
Bactiguard has won its first Swedish tender for central venous catheters (CVC), covering the Skåne region. The contract enables hospitals in the region to purchase Bactiguard’s anti-infective central venous catheters (BIP CVC) for at least two years.
"The University Hospital in Lund has been using our CVCs for approximately one year with very positive feedback, and therefore the county council has now decided to make the products available to all hospital in the region by including them in their latest tender,” says Nina Nilsson, SVP Sales and Marketing.
The contract runs from October 2018 to October 2020. Region Skåne may then extend the contract for another two (2) years. In accordance with Swedish tender law, the Skåne county council will execute the formal contract once the appeal period has expired, on 30 July 2018.
Since 2017, Bactiguard has a contract for its urinary catheters, BIP Foley Catheter and BIP Foley Catheter Silicone, with Region Skåne.
Central venous catheters with Bactiguard’s coating have been shown to reduce blood stream infections by up to50 percent in a randomized controlled clincial trial (RCT).1 Additionaly, a recently published study at Karolinska University Hospital showed that BIP CVC gave significantly fewer adverse events than a non-coated product.2
A common complication during treatment with CVCs, apart from infections, is thrombosis. An ex vivo study using Thrombin-Anti-Thrombin (TAT) as a marker for the risk of developing thrombosis, showed lower TAT levels when using BIP CVC compared to to uncoated catheters, which may indicate a lower risk of developing thrombosis.3
References:
1. Goldschmidt H.et al., Zbl. Bakt. 1995; 233: 215-223.
2. Björling G et al., J Biomed Mater Res B Appl Biomater. 2017 Nov 6.
3. Vafa Homann et al. 2015, J. Biomed. Mater. Res. Part B Appl. Biomater.
For further information, please contact:
Nina Nilsson, SVP Sales and Marketing, mobile: +46 70 214 87 49
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through license agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our license partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags: